<?xml version="1.0" encoding="UTF-8"?>
<results title="disease">
 <result pre="serious and life-threatening viruses. Some nucleoside analog drugs targeting specific" exact="viral" post="polymerases (acyclovir for herpesviruses, zidovudine for human immunodeficiency virus"/>
 <result pre="targeting specific viral polymerases (acyclovir for herpesviruses, zidovudine for human" exact="immunodeficiency" post="virus (HIV), and sofosbuvir for hepatitis C virus (HCV))"/>
 <result pre="herpesviruses, zidovudine for human immunodeficiency virus (HIV), and sofosbuvir for" exact="hepatitis" post="C virus (HCV)) have been successful in clinical trials"/>
 <result pre="have established the underlying molecular framework of nucleoside analogs. The" exact="primary" post="mechanism to explain the antiviral effect of nucleoside analogs"/>
 <result pre="of nucleoside analogs is based on their direct action on" exact="viral" post="polymerization. Nucleoside analogs are transported into the cells and"/>
 <result pre="into the cells and phosphorylated by the consecutive action of" exact="viral" post="or cellular kinases, eventually generating nucleotide triphosphates. Mature nucleotide"/>
 <result pre="similar to physiological nucleotides, can directly incorporate into the growing" exact="viral" post="genome during polymerization, resulting in the termination of chain"/>
 <result pre="Alternatively, nucleotide analogs can bind to the nucleotide-binding region on" exact="viral" post="polymerases and block the entry of incoming natural nucleotides."/>
 <result pre="consequently cause the depletion or imbalance of (d)NTP pools. As" exact="viral" post="replication is highly dependent on the availability of host"/>
 <result pre="of host nucleotides, a nucleotide-defective condition decreases the efficiency of" exact="viral" post="replication. A more recently proposed mechanism has been based"/>
 <result pre="against a broad range of RNA viruses, including Middle East" exact="respiratory" post="syndrome coronavirus (MERS-CoV), severe acute respiratory syndrome coronavirus (SARS-CoV),"/>
 <result pre="a broad range of RNA viruses, including Middle East respiratory" exact="syndrome" post="coronavirus (MERS-CoV), severe acute respiratory syndrome coronavirus (SARS-CoV), Zika"/>
 <result pre="RNA viruses, including Middle East respiratory syndrome coronavirus (MERS-CoV), severe" exact="acute" post="respiratory syndrome coronavirus (SARS-CoV), Zika virus (ZIKV), HCV, poliovirus"/>
 <result pre="viruses, including Middle East respiratory syndrome coronavirus (MERS-CoV), severe acute" exact="respiratory" post="syndrome coronavirus (SARS-CoV), Zika virus (ZIKV), HCV, poliovirus (PV),"/>
 <result pre="including Middle East respiratory syndrome coronavirus (MERS-CoV), severe acute respiratory" exact="syndrome" post="coronavirus (SARS-CoV), Zika virus (ZIKV), HCV, poliovirus (PV), influenza"/>
 <result pre="the family of Coronaviridae and are causative agents of severe" exact="viral" post="respiratory illness in humans. To efficiently select appropriate antiviral"/>
 <result pre="family of Coronaviridae and are causative agents of severe viral" exact="respiratory" post="illness in humans. To efficiently select appropriate antiviral drug"/>
 <result pre="[13]. More recently, gemcitabine was shown to effectively suppress ZIKV" exact="infection" post="and replication in human retinal pigment epithelium (RPE) cells,"/>
 <result pre="of the Flaviviridae family, can infect pregnant women and cause" exact="congenital" post="abnormalities such as microcephaly in infants, which has attracted"/>
 <result pre="can infect pregnant women and cause congenital abnormalities such as" exact="microcephaly" post="in infants, which has attracted increasing public attention as"/>
 <result pre="for the replication of HCV in Huh-7 cells and the" exact="infection" post="of HIV in U373-MAGI-CXCR4CEM cells, with estimated EC50s of"/>
 <result pre="of 12 nM and 16.3 nM, respectively [17,19], which were" exact="lower" post="concentrations than those used in cancer therapy [20]. In"/>
 <result pre="respectively [17,19], which were lower concentrations than those used in" exact="cancer" post="therapy [20]. In the case of HIV, the combination"/>
 <result pre="gemcitabine with decitabine, another nucleoside analog in clinical use for" exact="cancer" post="therapy, synergistically reduced HIV infectivity by increasing the viral"/>
 <result pre="for cancer therapy, synergistically reduced HIV infectivity by increasing the" exact="viral" post="mutation frequency [21]. In a follow up study, Clouser"/>
 <result pre="reported the antiviral effect of gemcitabine against HIV-related retrovirus, murine" exact="leukemia" post="virus (MuLV), in vitro (EC50 of 1.6 nM) and"/>
 <result pre="and found its strong inhibitory effect on Sindbis virus and" exact="herpes" post="simplex virus-1 (HSV-1) (&amp;gt;2 log reduction in virus titer)"/>
 <result pre="and human echovirus 6, and minimal effects on Bunyamwera virus," exact="measles" post="virus (MeV), and vaccinia virus [16]. The antiviral effect"/>
 <result pre="and minimal effects on Bunyamwera virus, measles virus (MeV), and" exact="vaccinia" post="virus [16]. The antiviral effect of gemcitabine on EVs,"/>
 <result pre="In this study, intranasal administration of gemcitabine significantly lowered the" exact="pulmonary" post="viral load and inflammation by decreasing proinflammatory cytokines, including"/>
 <result pre="this study, intranasal administration of gemcitabine significantly lowered the pulmonary" exact="viral" post="load and inflammation by decreasing proinflammatory cytokines, including TNF-α"/>
 <result pre="cytokines, including TNF-α and IL-1β, and the number of lung" exact="infiltrating" post="lymphocytes. More recently, Zhang et al. also identified gemcitabine"/>
 <result pre="with this possibility, there has been a report that the" exact="infection" post="of HSV-1, which is a representative DNA virus classified"/>
 <result pre="gemcitabine [16]. Most of the abovementioned viruses have, at best," exact="limited" post="prophylactic or therapeutic drugs as possible treatments. This is"/>
 <result pre="affected by gemcitabine, with a low nanomolar EC50, which was" exact="lower" post="than that used in cancer therapy [14,20]. Even for"/>
 <result pre="low nanomolar EC50, which was lower than that used in" exact="cancer" post="therapy [14,20]. Even for other viruses with a relatively"/>
 <result pre="achieved by the synergistic action of two antivirals with much" exact="lower" post="doses for each drug, which minimizes deleterious side effects"/>
 <result pre="in the innate immunity that defended the host against the" exact="virus infection." post="These results were consistent with a previous report that"/>
 <result pre="decades. Both have antiviral activities against viruses such as HCV," exact="hepatitis" post="E virus (HEV), MERS-CoV, dengue virus, yellow fever, hepatitis"/>
 <result pre="such as HCV, hepatitis E virus (HEV), MERS-CoV, dengue virus," exact="yellow fever," post="hepatitis B virus, West Nile virus (WNV), Chikungunya virus"/>
 <result pre="HCV, hepatitis E virus (HEV), MERS-CoV, dengue virus, yellow fever," exact="hepatitis" post="B virus, West Nile virus (WNV), Chikungunya virus (CHIKV),"/>
 <result pre="have been some reports that ISGs was induced in the" exact="absence of" post="JAK1 or STAT1 activation [43,44]. Despite limited data, we"/>
 <result pre="in the absence of JAK1 or STAT1 activation [43,44]. Despite" exact="limited" post="data, we speculate the scenario of ISG activation that"/>
 <result pre="has increased. In this regard, nucleoside analogs that directly target" exact="viral" post="RNA-dependent RNA polymerase and present a high barrier to"/>
 <result pre="1.JordheimL.P.DurantelD.ZoulimF.DumontetC.Advances in the development of nucleoside and nucleotide analogues for" exact="cancer" post="and viral diseasesNat. Rev. Drug Discov.20131244746410.1038/nrd401023722347 2.ElionG.B.The purine path"/>
 <result pre="the development of nucleoside and nucleotide analogues for cancer and" exact="viral" post="diseasesNat. Rev. Drug Discov.20131244746410.1038/nrd401023722347 2.ElionG.B.The purine path to chemotherapyScience1989244414710.1126/science.26499792649979"/>
 <result pre="2.ElionG.B.The purine path to chemotherapyScience1989244414710.1126/science.26499792649979 3.WhitleyR.J.AlfordC.A.HirschM.S.SchooleyR.T.LubyJ.P.AokiF.Y.HanleyD.NahmiasA.J.SoongS.J.Vidarabine versus acyclovir therapy in" exact="herpes" post="simplex encephalitisN. Eng. J. Med.198631414414910.1056/NEJM1986011631403033001520 4.KahnJ.O.LagakosS.W.RichmanD.D.CrossA.PettinelliC.LiouS.H.BrownM.VolberdingP.A.CrumpackerC.S.BeallG.et al.A controlled trial"/>
 <result pre="al.A controlled trial comparing continued zidovudine with didanosine in human" exact="immunodeficiency" post="virus infection. The niaid aids clinical trials groupN. Eng."/>
 <result pre="controlled trial comparing continued zidovudine with didanosine in human immunodeficiency" exact="virus infection." post="The niaid aids clinical trials groupN. Eng. J. Med.199232758158710.1056/NEJM1992082732709011353607"/>
 <result pre="trials groupN. Eng. J. Med.199232758158710.1056/NEJM1992082732709011353607 5.LawitzE.MangiaA.WylesD.Rodriguez-TorresM.HassaneinT.GordonS.C.SchultzM.DavisM.N.KayaliZ.ReddyK.R.et al.Sofosbuvir for previously untreated" exact="chronic hepatitis" post="C infectionN. Eng. J. Med.20133681878188710.1056/NEJMoa121485323607594 6.ThomasE.FeldJ.J.LiQ.HuZ.FriedM.W.LiangT.J.Ribavirin potentiates interferon action"/>
 <result pre="groupN. Eng. J. Med.199232758158710.1056/NEJM1992082732709011353607 5.LawitzE.MangiaA.WylesD.Rodriguez-TorresM.HassaneinT.GordonS.C.SchultzM.DavisM.N.KayaliZ.ReddyK.R.et al.Sofosbuvir for previously untreated chronic" exact="hepatitis" post="C infectionN. Eng. J. Med.20133681878188710.1056/NEJMoa121485323607594 6.ThomasE.FeldJ.J.LiQ.HuZ.FriedM.W.LiangT.J.Ribavirin potentiates interferon action"/>
 <result pre="6.ThomasE.FeldJ.J.LiQ.HuZ.FriedM.W.LiangT.J.Ribavirin potentiates interferon action by augmenting interferon-stimulated gene induction in" exact="hepatitis" post="c virus cell culture modelsHepatology201153324110.1002/hep.2398521254160 7.LeyssenP.BalzariniJ.de ClercqE.NeytsJ.The predominant mechanism"/>
 <result pre="by inhibition of imp dehydrogenaseJ. Virol.2005791943194710.1128/JVI.79.3.1943-1947.200515650220 8.DebingY.EmersonS.U.WangY.PanQ.BalzariniJ.DallmeierK.NeytsJ.Ribavirin inhibits in vitro" exact="hepatitis" post="e virus replication through depletion of cellular gtp pools"/>
 <result pre="talk between nucleotide synthesis pathways with cellular immunity in constraining" exact="hepatitis" post="e virus replicationAntimicrob. Agents Chemother.2016602834284810.1128/AAC.02700-1526926637 11.HertelL.W.BoderG.B.KroinJ.S.RinzelS.M.PooreG.A.ToddG.C.GrindeyG.B.Evaluation of the antitumor"/>
 <result pre="al.Repurposing of clinically developed drugs for treatment of middle east" exact="respiratory" post="syndrome coronavirus infectionAntimicrob. Agents Chemother.2014584885489310.1128/AAC.03036-1424841273 14.KuivanenS.BespalovM.M.NandaniaJ.IanevskiA.VelagapudiV.de BrabanderJ.K.KainovD.E.VapalahtiO.Obatoclax, saliphenylhalamide and"/>
 <result pre="of clinically developed drugs for treatment of middle east respiratory" exact="syndrome" post="coronavirus infectionAntimicrob. Agents Chemother.2014584885489310.1128/AAC.03036-1424841273 14.KuivanenS.BespalovM.M.NandaniaJ.IanevskiA.VelagapudiV.de BrabanderJ.K.KainovD.E.VapalahtiO.Obatoclax, saliphenylhalamide and gemcitabine"/>
 <result pre="infectionAntimicrob. Agents Chemother.2014584885489310.1128/AAC.03036-1424841273 14.KuivanenS.BespalovM.M.NandaniaJ.IanevskiA.VelagapudiV.de BrabanderJ.K.KainovD.E.VapalahtiO.Obatoclax, saliphenylhalamide and gemcitabine inhibit zika" exact="virus infection" post="in vitro and differentially affect cellular signaling, transcription and"/>
 <result pre="Agents Chemother.2014584885489310.1128/AAC.03036-1424841273 14.KuivanenS.BespalovM.M.NandaniaJ.IanevskiA.VelagapudiV.de BrabanderJ.K.KainovD.E.VapalahtiO.Obatoclax, saliphenylhalamide and gemcitabine inhibit zika virus" exact="infection" post="in vitro and differentially affect cellular signaling, transcription and"/>
 <result pre="inhibitor from an hsp90 inhibitor as a selective inhibitor of" exact="hepatitis" post="C virusPLoS ONE20127e3028610.1371/journal.pone.003028622347373 20.GrunewaldR.KantarjianH.DuM.FaucherK.TarassoffP.PlunkettW.Gemcitabine in leukemia: A phase I"/>
 <result pre="in vivoAntivir. Res.201714561310.1016/j.antiviral.2017.07.00328705625 23.LeeK.KimD.E.JangK.S.KimS.J.ChoS.KimC.Gemcitabine, a broad-spectrum antiviral drug, suppresses enterovirus" exact="infections" post="through innate immunity induced by the inhibition of pyrimidine"/>
 <result pre="and broad-spectrum in vitro antiviral activity against pandemic, seasonal and" exact="avian influenza" post="viruses affecting humansJ. Gen. Virol.2016971807181710.1099/jgv.0.00051227259985 25.MorreyJ.D.SmeeD.F.SidwellR.W.TsengC.Identification of active antiviral"/>
 <result pre="enzyme activity is a potential target for the inhibition of" exact="chikungunya" post="virus replication and virus induced apoptosis in cultured mammalian"/>
 <result pre="der LaanL.J.NeytsJ.JanssenH.L.MetselaarH.J.PeppelenboschM.P.PanQ.Calcineurin inhibitors stimulate and mycophenolic acid inhibits replication of" exact="hepatitis" post="E virusGastroenterology20141461775178310.1053/j.gastro.2014.02.03624582714 30.PanQ.de RuiterP.E.MetselaarH.J.KwekkeboomJ.de JongeJ.TilanusH.W.JanssenH.L.van der LaanL.J.Mycophenolic acid augments"/>
 <result pre="JongeJ.TilanusH.W.JanssenH.L.van der LaanL.J.Mycophenolic acid augments interferon-stimulated gene expression and inhibits" exact="hepatitis" post="C virus infection in vitro and in vivoHepatology2012551673168310.1002/hep.2556222213147 31.PanattoniA.D’AnnaF.TrioloE.Antiviral"/>
 <result pre="LaanL.J.Mycophenolic acid augments interferon-stimulated gene expression and inhibits hepatitis C" exact="virus infection" post="in vitro and in vivoHepatology2012551673168310.1002/hep.2556222213147 31.PanattoniA.D’AnnaF.TrioloE.Antiviral activity of tiazofurin"/>
 <result pre="acid augments interferon-stimulated gene expression and inhibits hepatitis C virus" exact="infection" post="in vitro and in vivoHepatology2012551673168310.1002/hep.2556222213147 31.PanattoniA.D’AnnaF.TrioloE.Antiviral activity of tiazofurin"/>
 <result pre="vitro culture systemTransplantation20057911611810.1097/01.TP.0000149338.97084.5F15714178 37.Lucas-HouraniM.DauzonneD.JordaP.CousinG.LupanA.HelynckO.CaignardG.JanvierG.Andre-LerouxG.KhiarS.et al.Inhibition of pyrimidine biosynthesis pathway suppresses" exact="viral" post="growth through innate immunityPLoS Pathog.20139e100367810.1371/journal.ppat.100367824098125 38.CheungN.N.LaiK.K.DaiJ.KokK.H.ChenH.ChanK.H.YuenK.Y.KaoR.Y.T.Broad-spectrum inhibition of common"/>
 <result pre="viral growth through innate immunityPLoS Pathog.20139e100367810.1371/journal.ppat.100367824098125 38.CheungN.N.LaiK.K.DaiJ.KokK.H.ChenH.ChanK.H.YuenK.Y.KaoR.Y.T.Broad-spectrum inhibition of common" exact="respiratory" post="RNA viruses by a pyrimidine synthesis inhibitor with involvement"/>
 <result pre="assessment of the druggability of their target for efficacy against" exact="respiratory" post="syncytial virus (RSV)Proc. Natl. Acad. Sci. USA20111086739674410.1073/pnas.101714210821502533 41.WangQ.Y.BushellS.QingM.XuH.Y.BonaviaA.NunesS.ZhouJ.PohM.K.Florez de"/>
 <result pre="host pyrimidine biosynthesisJ. Virol.2011856548655610.1128/JVI.02510-1021507975 42.SmeeD.F.HurstB.L.DayC.W.D282, a non-nucleoside inhibitor of influenza" exact="virus infection" post="that interferes with de novo pyrimidine biosynthesisAntivir. Chem. Chemother.20122226327210.3851/IMP210522516927"/>
 <result pre="pyrimidine biosynthesisJ. Virol.2011856548655610.1128/JVI.02510-1021507975 42.SmeeD.F.HurstB.L.DayC.W.D282, a non-nucleoside inhibitor of influenza virus" exact="infection" post="that interferes with de novo pyrimidine biosynthesisAntivir. Chem. Chemother.20122226327210.3851/IMP210522516927"/>
 <result pre="for both stat1-dependent and stat1-independent pathways in the control of" exact="primary" post="dengue virus infection in miceJ. Immunol.20051753946395410.4049/jimmunol.175.6.394616148142 45.SchogginsJ.W.Interferon-stimulated genes: Roles"/>
 <result pre="stat1-dependent and stat1-independent pathways in the control of primary dengue" exact="virus infection" post="in miceJ. Immunol.20051753946395410.4049/jimmunol.175.6.394616148142 45.SchogginsJ.W.Interferon-stimulated genes: Roles in viral pathogenesisCurr."/>
 <result pre="and stat1-independent pathways in the control of primary dengue virus" exact="infection" post="in miceJ. Immunol.20051753946395410.4049/jimmunol.175.6.394616148142 45.SchogginsJ.W.Interferon-stimulated genes: Roles in viral pathogenesisCurr."/>
 <result pre="dengue virus infection in miceJ. Immunol.20051753946395410.4049/jimmunol.175.6.394616148142 45.SchogginsJ.W.Interferon-stimulated genes: Roles in" exact="viral" post="pathogenesisCurr. Opin. Virol.20146404610.1016/j.coviro.2014.03.00624713352 Figure 1 The mechanism of antiviral"/>
 <result pre="(EC50 or IC50) Cell Toxicity (CC50) Ref. MERS-CoV (+)ssRNA Coronaviridae" exact="Viral" post="replication Vero E6 cells 1.2 μM &amp;gt;10 μM [13]"/>
 <result pre="E6 cells 1.2 μM &amp;gt;10 μM [13] SARS-CoV (+)ssRNA Coronaviridae" exact="Viral" post="replication Vero E6 cells 4.9 μM &amp;gt;10 μM [13]"/>
 <result pre="E6 cells 4.9 μM &amp;gt;10 μM [13] ZIKA (+)ssRNA Flaviviridae" exact="Viral" post="RNA and protein synthesis virus-mediated cell death RPE cells"/>
 <result pre="RPE cells 0.01 μM &amp;gt;10 μM [14] HCV (+)ssRNA Flaviviridae" exact="Viral" post="replication Huh-7 cells 12 nM &amp;gt;44 μM [19] Poliovirus"/>
 <result pre="Huh-7 cells 12 nM &amp;gt;44 μM [19] Poliovirus (+)ssRNA Picornaviridae" exact="Viral" post="replication RNA polymerase HeLa cells 0.3 μM &amp;gt;100 μM"/>
 <result pre="μM &amp;gt;100 μM [15] Influenza A virus (IAV) (−)ssRNA Orthomyxoviridae" exact="Viral" post="RNA transcription and replication virus entry RPE cells 0.068"/>
 <result pre="RPE cells 0.068 μM &amp;gt;10 μM [16] HIV ssRNA-RT Retroviridae" exact="Viral" post="replication U373-MAGI-CXCR4CEM cells 16.3 nM [17] MuLV ssRNA-RT Retroviridae"/>
 <result pre="Viral replication U373-MAGI-CXCR4CEM cells 16.3 nM [17] MuLV ssRNA-RT Retroviridae" exact="Viral" post="replication U373-MAGI-CXCR4CEM ls/Murine AIDS mouse model 1.6 nM [17]"/>
 <result pre="ls/Murine AIDS mouse model 1.6 nM [17] CVB3 (+)ssRNA Picornaviridae" exact="Viral" post="proliferation Viral replication Early step of virus infection Vero"/>
 <result pre="mouse model 1.6 nM [17] CVB3 (+)ssRNA Picornaviridae Viral proliferation" exact="Viral" post="replication Early step of virus infection Vero cells HeLa"/>
 <result pre="CVB3 (+)ssRNA Picornaviridae Viral proliferation Viral replication Early step of" exact="virus infection" post="Vero cells HeLa cells 0.4 μM 2 μM &amp;gt;50"/>
 <result pre="(+)ssRNA Picornaviridae Viral proliferation Viral replication Early step of virus" exact="infection" post="Vero cells HeLa cells 0.4 μM 2 μM &amp;gt;50"/>
 <result pre="2 μM &amp;gt;50 μM &amp;gt;50 μM [18] EV71 (+)ssRNA Picornaviridae" exact="Viral" post="proliferation Viral replication Vero cells 1 μM &amp;gt;50 μM"/>
 <result pre="&amp;gt;50 μM &amp;gt;50 μM [18] EV71 (+)ssRNA Picornaviridae Viral proliferation" exact="Viral" post="replication Vero cells 1 μM &amp;gt;50 μM [18] HRV"/>
 <result pre="Vero cells 1 μM &amp;gt;50 μM [18] HRV (+)ssRNA Picornaviridae" exact="Viral" post="RNA synthesis HeLa cells/Mouse 1–5 μM &amp;gt;50 μM [18,22]"/>
</results>
